Dr Jonathan Riess on the Potential of IO102-IO103, the Cancer Vaccine Landscape
Jonathan Riess discussed combining IO102-IO103 cancer vaccine with pembrolizumab for advanced SCCHN, presenting a 44.4% partial response rate and safety data at ESMO 2024, suggesting potential for larger studies.
Reference News
Dr Jonathan Riess on the Potential of IO102-IO103, the Cancer Vaccine Landscape
Jonathan Riess discussed combining IO102-IO103 cancer vaccine with pembrolizumab for advanced SCCHN, presenting a 44.4% partial response rate and safety data at ESMO 2024, suggesting potential for larger studies.